Horizon Therapeutics gains as FTC withdraws in-house trial on Amgen deal
JHVEPhoto/iStock Editorial via Getty Images
Horizon Therapeutics (NASDAQ:HZNP) rose 5% in after-hours trading after the Federal Trade Commission withdrew an in-house trial over its challenge to the $28 billion sale to Amgen (NASDAQ:AMGN) deal.
The antitrust regulator asked for a delay and the matter was withdrawn from adjudication, according to an FTC court filing, which was disclosed on Friday. 
The FTC said it "believes it would be appropriate to take steps to allow for discussion with the Commission regarding the proper resolution of this matter," according to a separate filing. 
The filing references a July 19 hearing where Administrative Judge Michael Chappell urged the parties to enter into talks to settle the matter, and the companies said they were open to the possibility. 
Developing story ...

More on Amgen, Horizon Therapeutics, etc.

Horizon Therapeutics: Can Investors Profit From Amgen Deal Confusion?
Improved Outlook For Horizon Therapeutics And Amgen
Amgen Is Back!
Amgen Gives You Growth, Dividend Growth, And Value
Amgen Inc. 2023 Q2 - Results - Earnings Call Presentation

Amgen Inc. (AMGN) Q2 2023 Earnings Call Transcript
Amgen: Huge Potential With Biosimilars And GLP-1
Amgen: Is The 3.79% Dividend Yield Worth The Fuss?
FTC likely to lose its challenge to the Horizon/Amgen deal, legal experts say - analyst
Amgen says FTC case to block Horizon Therapeutics deal `defies logic'
Horizon Therapeutics gains amid speculation on potential FTC settlement on Amgen
Horizon Therapeutics, Activision among best bets for M&A deals to close
2023 shaping up to be biggest year for biopharma M&A since pandemic